olema.com
Open in
urlscan Pro
35.224.55.107
Public Scan
Submitted URL: http://www.olema.com/
Effective URL: https://olema.com/
Submission: On October 08 via api from US — Scanned from DE
Effective URL: https://olema.com/
Submission: On October 08 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
Skip to content Toggle navigation Home About Science * Publications Pipeline Patients Investors & Media Careers * Culture Contact * Privacy Policy * Terms of Use * * OUR GOALS ARE BIG. OUR MISSION IS POWERFUL. OUR GOALS ARE BIG. OUR MISSION IS POWERFUL. OUR GOALS ARE BIG. OUR MISSION IS POWERFUL. OUR GOALS ARE BIG. OUR MISSION IS POWERFUL. 1. 2. 3. 4. button/interactions/pause circle@2x CHALLENGING OURSELVES TO IMPROVE THE LIVES OF OTHERS We exist to develop therapies that offer the potential to improve outcomes for women living with cancer. We approach these goals with a single-minded focus. At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, to achieve our goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives. About Olema LATEST NEWS For more information, visit the Investors & Media section of our website. See All News Open in a new tab October 4th, 2022 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Open in a new tab September 6th, 2022 Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference Open in a new tab September 1st, 2022 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) For more information, visit the Investors & Media section of our website. See All News OUR NOVEL APPROACH TO ADVANCING BREAST CANCER THERAPY Many forms and stages of cancer continue to elude control. Malignant cells adapt and exploit mutations and redundancies, so partial targeting leaves vulnerabilities. At Olema, we have no patience for incomplete efforts, so we’re developing OP-1250, an orally bioavailable Complete Estrogen Receptor Antagonist, or CERAN, and selective ER degrader, or SERD, for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Our Pipeline LIFE AT OLEMA I was inspired to join Olema by the enthusiasm of the founding team both for the impact they are hoping to make on treatment for ER+ breast cancer and the science driving their research. I believe Olema has a chance to make a real difference improving the treatment options for women with breast cancer and I’m excited to be a part of their journey. — Alison Parisian Scientist at Olema Oncology Careers Onto something bigger, together. Join Us San Francisco 512 2nd St., 4th Floor San Francisco, CA 94107 Cambridge 245 Main Street, 4th Floor Cambridge, MA 02142 Contact info@olema.com * * * ©2022 Olema Oncology. Olema, Olema Oncology and our logo are trademarks of Olema Oncology. All rights reserved. * Privacy Policy * Terms of Use This site uses cookies to offer you a better browsing experience. Find out more on how we use cookies and how you can change your settings in our Privacy & Cookie Policy. Accept